Spectrum Pharmaceuticals Inc., of Henderson, Nev., reported total product sales of $25.8 million for the first quarter, including net sales of $2.6 million for folate analogue Fusilev (levoleucovorin), $9.3 million for peripheral T-cell lymphoma drug Folotyn (pralatrexate), $2.8 million for radioimmunotherapeutic Zevalin (ibritumomab tiuxetan), $2 million for Marqibo (vincristine sulfate liposome injection), $2.9 million for HDAC inhibitor Beleodaq (belinostat) and $6.3 million for Evomela (melphalan). Spectrum recorded a net loss of $23 million, or 29 cents per basic and diluted share. Non-GAAP net income totaled $300,000, or 1 cent per share, beating estimates of a net loss of 2 cents per share.